A Swiss microbiota biotherapeutics and mucosal vaccines company with two technology platforms: ApyraVax for the generation of innovative mucosal vaccines; ApyraMed with indication as enhancer in cancer immunotherapy and corrector of dysbiosis induced by antibiotic treatments and unhealthy diet.
Facts & figures
-
Type of organizationPrivate company
-
Year of foundation2018
-
Number of employees in Switzerland1-9